Ehlers-Danlos syndrome is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnostic and therapeutic programs. Treatment and management of Ehlers-Danlos syndrome vascular therapies require individualized development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multi-dimensional management. In recent years, with the development of therapeutic-focused, immune-regulatory therapies and precision medicine, significant improvements have been made to many of the previously difficult-to-treat autoimmune and rheumatoid immune disorders.
The platform serves the China International Medical Service System, which combines national and international authorities in the field of autoimmunity and rheumatic immunity to provide the following services to patients: 1. Remote pre-diagnosis: pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: arranging face-to-face diagnostics with authorities, developing personalized treatment plans; 3.
Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.